title: Elevation of serum KL-6 levels in 3 patients with rheumatoid arthritis treated with adalimumab.
abstract: We describe 3 cases of rheumatoid arthritis presenting with elevated serum KL-6 levels during treatment with adalimumab, which was discontinued because of suspected onset of complications. However, no complications were observed following discontinuation despite comprehensive assessments, and KL-6 levels subsequently returned to baseline levels. In our institutes, 3 out of 29 cases treated with adalimumab showed elevated KL-6 levels. The baseline levels were 445, 347, and 547 U/ml, while the peak levels were 1010, 546, and 2007 U/ml, respectively. The elevated KL-6 levels seem to have been innocuous; nevertheless, further careful observation is deemed necessary.
authors.affiliation: Department of Orthopaedic Surgery, Shuwa General Hospital, 1200, Yawarasinden, Kasukabe, Saitama 344-0035, Japan. koiwam@shuwa.or.jp
authors.forename: Masahito
authors.initials: M
authors.lastname: Koiwa
authors.forename: Susumu
authors.initials: S
authors.lastname: Goto
authors.forename: Kenji
authors.initials: K
authors.lastname: Takenouchi
authors.forename: Kenji
authors.initials: K
authors.lastname: Takahasi
authors.forename: Toshikazu
authors.initials: T
authors.lastname: Kamada
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Nakamura
mesh_terms: D000068879:Adalimumab; D000368:Aged; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects*; D018501:Antirheumatic Agents / Q000009:adverse effects*; D001172:Arthritis, Rheumatoid / Q000097:blood* / Q000175:diagnosis / Q000188:drug therapy; D003141:Communicable Diseases / Q000175:diagnosis; D003937:Diagnosis, Differential; D005260:Female; D006801:Humans; D008171:Lung Diseases / Q000175:diagnosis; D008875:Middle Aged; D018396:Mucin-1 / Q000097:blood*; D028761:Withholding Treatment
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; C060192:MUC1 protein, human; D018396:Mucin-1; D000068879:Adalimumab